GenSight Biologics S A : Notice of General Meeting to be held on the 21th of June, 2023
CONVENING OF THE COMBINED GENERAL MEETING ON MAY 25, 2022 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023
Source: marketscreener.com
Temporary Authorisation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Temporary Authorisation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Temporary Authorisation Today - Breaking & Trending Today
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease | Comunicados | Edición USA
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease 1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare...
Source: efe.com
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease Research academic teams of the consortium - Institut de Recherche Saint Louis 1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab ElsaLys Biotech utilising in silico studies to accelerate the European approval...
Source: finanznachrichten.de